Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Non-Hodgkin's Lymphoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    587 result(s) found for: Non-Hodgkin's Lymphoma. Displaying page 13 of 30.
    «« First « Previous 9  10  11  12  13  14  15  16  17  Next» Last»»
    EudraCT Number: 2021-003397-32 Sponsor Protocol Number: MK2140-004 Start Date*: 2021-12-21
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Medical condition: Treatment of participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) PL (Trial now transitioned) NO (Trial now transitioned) EE (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003256-22 Sponsor Protocol Number: UKM17_0017 Start Date*: 2018-03-22
    Sponsor Name:Universitätsklinikum Münster
    Full Title: Ibrutinib and Standard Immuno-Chemotherapy (R-CHOEP-14) In Younger, High-Risk Patients with Diffuse Large B-Cell Lymphoma
    Medical condition: diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000669-19 Sponsor Protocol Number: MO28107 Start Date*: 2012-07-30
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A COMPARATIVE, RANDOMIZED, PARALLEL-GROUP, MULTI-CENTRE, PHASE IIIB STUDY TO INVESTIGATE THE EFFICACY OF SUBCUTANEOUS (SC) RITUXIMAB VERSUS INTRAVENOUS (IV) RITUXIMAB BOTH IN COMBINATION WITH CHOP ...
    Medical condition: Adult patients aged 18-80 years with previously untreated CD20-positive diffuse large B-cell lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FI (Completed) NL (Completed) GR (Completed) GB (Completed) IT (Completed) IE (Completed) FR (Completed) BE (Completed) BG (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001100-40 Sponsor Protocol Number: PIX203 Start Date*: 2008-05-23
    Sponsor Name:Cell Therapeutics Europe S.r.l.
    Full Title: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone plus Rituximab (CHOP-R) and Cyclophosphamide, Pixantrone, Vincristine, Prednisone plus Rituximab (CPOP-R) in Patients with Diffuse Large-B-c...
    Medical condition: Diffuse large B-cell lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000270-23 Sponsor Protocol Number: Z BEAM 2 Start Date*: 2007-05-21
    Sponsor Name:GELA
    Full Title: TARGETED INTENSIFICATION BY A PREPARATIVE REGIMEN FOR PATIENTS WITH HIGH-GRADE B-CELL LYMPHOMA UTILIZING STANDARD-DOSE YTTRIUM-90 IBRITUMOMAB TIUXETAN (ZEVALIN) RADIOIMMUNOTHERAPY (RIT) COMBINED WI...
    Medical condition: Diffuse Large B cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012818 Diffuse large B-cell lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005371-16 Sponsor Protocol Number: D4302C00001 Start Date*: 2012-07-30
    Sponsor Name:Rigel Pharmaceuticals, Inc.
    Full Title: Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    Medical condition: Diffuse Large B-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10012820 Diffuse large B-cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003893-29 Sponsor Protocol Number: BAY80-6946/17067 Start Date*: 2015-06-25
    Sponsor Name:Bayer AG
    Full Title: A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin’...
    Medical condition: Patients with relapsed indolent B-cell non-Hodgkin's lymphoma
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029600 Non-Hodgkin's lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) PT (Completed) DE (Prematurely Ended) ES (Prematurely Ended) BE (Completed) LT (Completed) HU (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended) BG (Prematurely Ended) LU (Completed) GR (Completed) SK (Prematurely Ended) IT (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2014-003060-20 Sponsor Protocol Number: CCTL019C2201 Start Date*: 2015-10-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
    Medical condition: Adult patients ≥ 18 years with relapsed or refractory DLBCL, having failed 2 or more lines of therapy and not eligible for HSCT
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) NO (Completed) NL (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005520-16 Sponsor Protocol Number: BO20603 Start Date*: 2007-05-02
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Ensayo clínico de fase III multicéntrico, randomizado, doble ciego, controlado con placebo, para comparar la eficacia de bevacizumab en combinación con rituximab y CHOP (RA CHOP) frente a rituxima...
    Medical condition: Pacientes con linfoma difuso de células B grandes (LDCBG) CD20-positivo no tratados previamente, que presentan enfermedad de riesgo intermedio-bajo, intermedio-alto o alto, de acuerdo con el índic...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012818 Diffuse large B-cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) FR (Completed) CZ (Completed) GR (Completed) PT (Completed) GB (Completed) SE (Completed) DE (Completed) IT (Completed) PL (Completed) SK (Completed) LT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2004-002692-16 Sponsor Protocol Number: APL-B-012-02 Start Date*: 2004-10-27
    Sponsor Name:PharmaMar SA unipersonal
    Full Title: A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory Indolent Non-Hodgkin’s Lymphoid Neoplasms.
    Medical condition: Non-Hodgkin’s Lymphomas (NHLs) relapsing or refractory
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-002197-34 Sponsor Protocol Number: 04/Q1104/27 Start Date*: 2004-12-14
    Sponsor Name:University College London
    Full Title: A phase III multicentre randomised clinical trial comparing rituximab with CHOP given every 14 days and rituximab with CHOP given every 21 days for the treatment of patients with newly diagnosed d...
    Medical condition: Newly diagnosed diffuse large B cell non-Hodgkin's lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-000454-44 Sponsor Protocol Number: R-C5R 2006 Start Date*: 2007-05-23
    Sponsor Name:Groupe d’Etude des Lymphomes de l’Adulte (GELA)
    Full Title: Etude prospective multicentrique de phase II évaluant l’adjonction du rituximab et du DepoCyte® en intrathécal au protocole de chimiothérapie C5R chez les patients âgés de 18 à 60 ans porteurs de l...
    Medical condition: Patiens with primary cerebral or oculocerebral NHL not previously treated with chemotherapy or radiotherapy and diffuse large B-cell lymphomas, with cerebral and / or neuromeningeal involvement at ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012820 Diffuse large B-cell lymphoma NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003494-29 Sponsor Protocol Number: 108929 Start Date*: 2012-04-26
    Sponsor Name:Stanford University School of Medicine
    Full Title: FLT-PET vs FDG-PET Response Assessment in Diffuse Large B-cell Lymphoma
    Medical condition: Patients with agressive lymphoma in first therapy
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001491-20 Sponsor Protocol Number: STORM-2011 Start Date*: 2012-10-04
    Sponsor Name:Ruprecht-Karls University Heidelberg, Medical Faculty
    Full Title: A phase II trial to evaluate the safety, feasibility and efficacy of a salvage therapy consisting of the mTOR inhibitor Temsirolimus (Torisel™) added to the standard therapy of Rituximab and DHAP f...
    Medical condition: Diffuse large B-cell lymphoma with documented relapse or progression following at least one but a maximum of two prior treatments, aged older than 18 years
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004943 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001597-29 Sponsor Protocol Number: HEM2012ZrOR001 Start Date*: 2012-07-10
    Sponsor Name:VU University Medical Center
    Full Title: Tumor uptake of 89Zirconium-ofatumumab and 89Zirconium-rituximab in diffuse large B cell lymphoma patients
    Medical condition: Diffuse large B cell lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003821-25 Sponsor Protocol Number: CHUBX 2007/11 Start Date*: 2007-10-05
    Sponsor Name:CHU de Bordeaux
    Full Title: Etude de la tolérance et de l'efficacité du Zevalin dans un conditionnement à intensité réduite avant allogreffe de cellules souches hématopoïétiques dans les lymphomes B CD20+ agressifs de l'adult...
    Medical condition: L’association du Zevalin®, anticorps monoclonal anti-CD20 radio marqué, à une chimiothérapie immunosuppressive permettrait d’accroître l’efficacité d’un conditionnement à intensité réduite à base d...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012820 Diffuse large B-cell lymphoma NOS LLT
    9.1 10026799 Mantle cell lymphoma NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-003255-30 Sponsor Protocol Number: 20150291 Start Date*: 2017-10-04
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-Cell Lymphoma Post-autologous Hematopoietic Stem-cell Trans...
    Medical condition: High-risk Diffuse Large B-cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005338-13 Sponsor Protocol Number: ONC-2011-004 Start Date*: 2013-08-17
    Sponsor Name:Istituto Clinico Humanitas - Humanitas Cancer Center
    Full Title: OFATUMUMAB-BENDAMUSTINE FOR RELAPSED/REFRACTORY INDOLENT LYMPHOMA: A MULTICENTER PHASE 2 TRIAL
    Medical condition: Non-Hodgkin's Follicular and Non-Follicular indolent lymphomas, relapsed/refractory
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051812 Small cell lymphocytic lymphoma LLT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003908 B-cell small lymphocytic lymphoma PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029460 Nodal marginal zone B-cell lymphoma PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025342 Lymphoplasmacytoid lymphoma/immunocytoma PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065856 Non-Hodgkin's lymphoma unspecified histology indolent PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10047801 Waldenstrom's macroglobulinaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-005744-29 Sponsor Protocol Number: GCT3013-06 Start Date*: 2022-10-06
    Sponsor Name:Genmab A/S
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, GLOBAL, PHASE 2 TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF EPCORITAMAB (GEN3013; DUOBODY®-CD3×CD20) AS MONOTHERAPY OR IN COMBINATION WITH LENALIDOMIDE AS FI...
    Medical condition: B-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) IT (Trial now transitioned) CZ (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003410-39 Sponsor Protocol Number: D8242C00001 Start Date*: 2023-01-19
    Sponsor Name:AstraZeneca AB
    Full Title: A Modular Phase I/II, Open-label, Dose Escalation and Expansion, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0466 as Monotherapy or in Com...
    Medical condition: Advanced Non-Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10025315 Lymphoma malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FR (Completed) IT (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 9  10  11  12  13  14  15  16  17  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 23:15:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA